ID: h-2e7eb2ea
Hypothesis
Enteric Nervous System Prion-Like Propagation Blockade
Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve.
EvidencePending (0%)📖 24 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve. Targeted antimicrobial therapy against specific pathogenic strains could interrupt this ascending pathological cascade.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Dysbiotic Gut<br/>Microbiome"] --> B["Bacterial LPS<br/>Production"]
B --> C["TLR4 Activation<br/>on Enteric Neurons"]
C --> D["MyD88 and TRIF<br/>Recruitment"]
D --> E["NF-kappaB and IRF3<br/>Signaling"]
E --> F["Pro-inflammatory<br/>Cytokine Release<br/>(IL-1beta, TNF-alpha)"]
F --> G["Neuroinflammation<br/>in ENS"]
G --> H["Enhanced alpha-Synuclein<br/>Aggregation"]
H --> I["Prion-like<br/>alpha-Synuclein<br/>Formation"]
I --> J["Cell-to-Cell<br/>Transmission<br/>in ENS"]
J --> K["Vagus Nerve<br/>Propagation"]
K --> L["CNS alpha-Synuclein<br/>Pathology"]
L --> M["Neurodegeneration"]
N["TLR4 Antagonists"] -->|"Therapeutic<br/>Blockade"| C
O["Microbiome<br/>Restoration"] -->|"Therapeutic<br/>Intervention"| A
P["Vagotomy"] -->|"Surgical<br/>Intervention"| K
classDef normal fill:#4fc3f7,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef molecular fill:#ce93d8,color:#0d0d1a
class A,B pathology
class C,D,E,F,G,H,I,J,K molecular
class L,M outcome
class N,O,P therapeutic⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Supports
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.
Supports
Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform.
Supports
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
Supports
Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein.
Contradicts
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.
Contradicts
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.
📖 Linked Papers (20)Export BibTeX ↗
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.
International journal of molecular sciences (2025) · PubMed:41465422 ↗
5 figures

Figure 1
Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disea...

Figure 2
Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory med...
Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration.
Nat Commun (2020) · PubMed:32170061 ↗
7 figures

Fig. 1
Neuron-released α-synuclein is engulfed by microglia in vivo. a , b , f , g Brain sections from AAV-GFP ( n = 768 cells, six animals) and AAV- h α-Syn-inje...

Fig. 2
Microglia-engulfed α-synuclein is degraded by autophagy. a , b , c Cultured primary microglia from WT mice ( a and left panels of b ) and GFP–LC3-transgeni...
The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model.
Life sciences (2020) · PubMed:31790685 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice.
Scientific reports (2019) · PubMed:30962497 ↗
9 figures

Figure 1
Illustration of the protocols, including the time line of the experiments and tests.

Figure 2
LPS-induced memory defects in the MWM test and passive avoidance performance test. ( A ) Mice showed impaired learning and memory function after injections of L...
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Cancer chemotherapy and pharmacology (2017) · PubMed:28011980 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Co-exposure to polystyrene nanoplastics and glyphosate exacerbates NETs-mediated pyroptosis by activating the NLRP3 inflammasome in mouse liver.
Ecotoxicology and environmental safety (2025) · PubMed:40554107 ↗
No figures
Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model.
Phytomedicine : international journal of phytotherapy and phytopharmacology (2024) · PubMed:38552431 ↗
No figures
Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model.
Phytomedicine : international journal of phytotherapy and phytopharmacology (2024) · PubMed:38552431 ↗
No figures
The role of the microbiota in glaucoma.
Molecular aspects of medicine (2023) · PubMed:37866106 ↗
No figures
The role of the microbiota in glaucoma.
Molecular aspects of medicine (2023) · PubMed:37866106 ↗
No figures
📙 Related Wiki Pages (15)
PBKR03entityMYO6 — Myosin VIgeneTLR4 GenegeneToll-Like Receptor 4 (TLR4)proteinSNCA — Alpha-SynucleingeneSNCA — Alpha-Synuclein Gene Entity PagegeneGlobus Pallidus Externus GABAergic in NecellHippocampal Granule Cells in NeurodegenecellAxon Guidance Pathways in NeurodegeneratmechanismAAV Capsid Engineering for CNS-Targeted ideaMicroglial Priming and Innate Immune ToltherapeuticGSK3 Beta in NeurodegenerationmechanismRibonuclease κ and Circular RNAs: A New mechanismBDNF Signaling Pathway in NeurodegeneratmechanismSigma-1 Receptor Agonists for Neurodegentherapeutic
🏥 Translation
🧬 3D Protein Structure — TLR4
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TLR4, SNCA from GTEx v10.
💉 Clinical Trials (5)Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TLR4, SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.4 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0603
Events (7d)
0
Price History
▲5.3%💾 Resource Usage
LLM Tokens
34,972
$0.2158
Total Cost
$0.2158
🔮 Predictions
🔎 Predictions vs Observations3 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention be therapeutically targeted across multiple neurodegenerative conditions | be therapeutically targeted across multiple neurodegenerative conditions | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention be essential for patient stratification and treatment monitoring | be essential for patient stratification and treatment monitoring | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously | provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (3)
pendingconf 50%
If hypothesis is true, intervention be essential for patient stratification and treatment monitoring
Predicted outcome: be essential for patient stratification and treatment monitoring
Falsification: Intervention fails to be essential for patient stratification and treatment monitoring
pendingconf 50%
If hypothesis is true, intervention be therapeutically targeted across multiple neurodegenerative conditions
Predicted outcome: be therapeutically targeted across multiple neurodegenerative conditions
Falsification: Intervention fails to be therapeutically targeted across multiple neurodegenerative conditions
pendingconf 50%
If hypothesis is true, intervention provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Predicted outcome: provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Falsification: Intervention fails to provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.